01
10
Global Morpho Pharma introduced to the world at EANM 18
The annual EANM gathering (European Association of Nuclear Medicine) is widely acknowledged as the world’s most important nuclear medicine conference. This was the global stage chosen by Global Morpho Pharma for its first introduction to the world’s nuclear medicine community, in the presence of the group’s partners and team of experts. GMP unveiled its strategy to develop a global distribution network for therapeutic radionuclides, a process already underway in the USA with a partnership focusing on clinical quality Lutetium-177.